Hyperfine (HYPR) Stock Price, News & Analysis

Company Overview

Hyperfine Inc (NASDAQ: HYPR) is a medical technology company specializing in the development and commercialization of portable magnetic resonance imaging (MRI) systems. Its flagship product, the Swoop® Portable MR Imaging System, employs low-field magnet technology to deliver point-of-care neuroimaging in settings where traditional MRI scanners are impractical. By eliminating the need for specialized infrastructure such as shielded rooms and heavy gantries, Hyperfine aims to broaden access to critical imaging services in emergency departments, intensive care units, and remote healthcare facilities.

In addition to its core hardware offering, Hyperfine provides an integrated software platform that enables secure image transmission, cloud-based storage and on-demand interpretation. This connectivity allows clinicians to consult with specialists in real time, accelerating diagnosis and treatment decisions for conditions such as stroke, traumatic brain injury and intracranial hemorrhage. The company also offers training, installation support and application development services to ensure seamless adoption across diverse clinical environments.

Founded in 2014 and headquartered in Guilford, Connecticut, Hyperfine was co-founded by a team of entrepreneurs and imaging experts seeking to transform the MRI market. The Swoop system received 510(k) clearance from the U.S. Food and Drug Administration in 2020, followed by CE mark authorization for distribution in Europe. Since then, the company has expanded its commercial footprint to include academic medical centers, community hospitals and mobile care units across North America, Europe and select international markets.

Under the leadership of President and Chief Executive Officer Todd Fruchterman, Hyperfine has forged strategic partnerships with healthcare providers, research institutions and non-profit organizations to validate its technology in clinical studies and real-world applications. The executive team, which brings together expertise in imaging science, regulatory affairs and global sales, continues to pursue innovation aimed at lowering the cost and complexity of diagnostic imaging while improving patient outcomes worldwide.

Key Stats

• Today's Range: $0.76 to $0.79
• 50-Day Range: $0.54 to $0.86
• 52-Week Range: $0.53 to $1.90
• Volume: 169,710 shs
• Average Volume: 897,852 shs
• Market Capitalization: $60.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.06
• Consensus Rating: Moderate Buy

Hyperfine Stock Analysis - MarketRank™

Hyperfine scored higher than 38% of companies evaluated by MarketBeat, and ranked 682nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hyperfine has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hyperfine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hyperfine are expected to grow in the coming year, from ($0.57) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperfine is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperfine is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hyperfine has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.61% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperfine has recently increased by 129.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperfine does not currently pay a dividend.

Dividend Growth

Hyperfine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.61% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperfine has recently increased by 129.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Hyperfine this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for HYPR on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hyperfine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,610.00 in company stock.

Percentage Held by Insiders

30.98% of the stock of Hyperfine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.03% of the stock of Hyperfine is held by institutions.

HYPR Stock Analysis - Frequently Asked Questions

How have HYPR shares performed this year?

Hyperfine's stock was trading at $0.88 at the beginning of the year. Since then, HYPR stock has decreased by 11.7% and is now trading at $0.7773.

How were Hyperfine's earnings last quarter?

Hyperfine, Inc. (NASDAQ:HYPR) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $2.82 million. Hyperfine had a negative trailing twelve-month return on equity of 74.19% and a negative net margin of 343.42%.
Read the conference call transcript.

How do I buy shares of Hyperfine?

Shares of HYPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hyperfine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hyperfine investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Paycom Software (PAYC), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HYPR
• CIK: 1833769
• Web: hyperfine.io
• Phone: 866-796-6767
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.06
• High Stock Price Target: $1.50
• Low Stock Price Target: $0.68
• Potential Upside/Downside: +36.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.72 million
• Net Margins: -343.42%
• Pretax Margin: -343.42%
• Return on Equity: -74.19%
• Return on Assets: -62.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.07
• Quick Ratio: 5.48

Sales & Book Value

• Annual Sales: $12.89 million
• Price / Sales: 4.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 77,830,000
• Free Float: 53,720,000
• Market Cap: $60.50 million
• Optionable: Optionable
• Beta: 1.01